In that regard, PDL-1 blockers and PD-1 blockade have been reported to be effective in patients with an aggressive NK/T-cell lymphoma at relapse, as tumor cells harboring EBV genome upregulate PDL-1 (22). The gene discussed is PDCD1; the disease is T-cell non-Hodgkin lymphoma.